AMBRX, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2003-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.ambrx.com
ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
Phase 2
Withdrawn
- Conditions
- HER2 Mutation-Related TumorsHER2 Amplified Solid Tumors
- Interventions
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- Ambrx, Inc.
- Registration Number
- NCT05041972
- Locations
- 🇺🇸
Mount Sinai Medical Center, Miami Beach, Florida, United States
🇺🇸AMR Kansas City, Kansas City, Missouri, United States
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Ambrx, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT04829604
- Locations
- 🇰🇷
Research Site, Suwon, Korea, Republic of
A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)
- First Posted Date
- 2017-08-21
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Ambrx, Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT03255070
- Locations
- 🇺🇸
USC Norris Cancer Hospital, Los Angeles, California, United States
🇺🇸UCLA Hematology-Oncology, Santa Monica, California, United States
🇦🇺Monash Health, Clayton, Victoria, Australia
Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2009-10-12
- Lead Sponsor
- Ambrx, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00778518
- Locations
- 🇭🇺
Accelsiors CRO and Consultancy Services, Budapest, Hungary
© Copyright 2025. All Rights Reserved by MedPath